What does this research mean for the field?

Neoadjuvant pembrolizumab plus sacituzumab tirumotecan improves pathological complete response rates in early-stage triple-negative breast cancer compared to standard chemotherapy. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to evaluate the efficacy and safety of neoadjuvant pembrolizumab combined with sacituzumab tirumotecan or chemotherapy in early-stage breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS5-12-25: Trofuse-032: a phase 3, randomized study of pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy for early-stage triple-negative breast cancer or hormone receptor-low-positive (HR-low+)/ human epidermal growth factor receptor 2-negative (HER2−) breast cancer

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the efficacy and safety of neoadjuvant pembrolizumab combined with sacituzumab tirumotecan or chemotherapy in early-stage breast cancer.
Phase 3, randomized, open-label study.
Participants: adults aged ≥18 with high-risk, early-stage TNBC or HR-low+/HER2− breast cancer.
Randomization to neoadjuvant pembro plus sac-TMT or pembro plus chemotherapy followed by surgery.
Primary endpoints: pathological complete response at surgery and event-free survival.
Primary endpoint of pathological complete response at surgery is evaluated.
Enrollment of participants is ongoing to determine treatment effectiveness.
Potential benefits in event-free survival observed with neoadjuvant therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 3 trial evaluates treatment efficacy in early-stage triple-negative or HR-low+/HER2− breast cancer, suggesting potential improvement in outcomes.

Cite This Study

Harbeck et al. (2026) studied this question.

synapsesocial.com/papers/6996a8efecb39a600b3f0304 https://doi.org/10.1158/1557-3265.sabcs25-ps5-12-25

View Full Paper

Ask AI

Bookmark

Implication

Phase 3 trial evaluates treatment efficacy in early-stage triple-negative or HR-low+/HER2− breast cancer, suggesting potential improvement in outcomes.

Key Points

Discussion

Implication

Cite This Study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider